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lipoprotein (LDL)-cholesterol (LDL-C) > 135 mg/dL 
(>3.5 mmol/L), high-density lipoprotein (HDL)-cholesterol 
(HDL-C) < 35 mg/dL (<0.9 mmol/L) in men or <40 mg/dL 
(<1.0 mmol/L) in women, and a ratio of total cholesterol to 
HDL-cholesterol > 5] has been identified as a risk factor in 
the development of micro- and macrovascular complications 
in diabetic patients including DN.[4] Lipids induce renal 
injury by various pathophysiological mechanisms but data 
on the role of dyslipidemia in increasing the susceptibility 
to nephropathy or ESRD in DM patients are sparse and 
inconclusive. Moorhead et al. in 1982 hypothesized that 
hyperlipidemia promotes progression of chronic renal 
Introduction
Diabetic nephropathy (DN) is a common complication of 
diabetes mellitus (DM). It is also a common cause of end-
stage renal disease (ESRD) worldwide and is prevalent in our 
environment.[1-3] With the increasing epidemic of diabetes 
mellitus and its far reaching complications worldwide, 
the implication in a developing country like Nigeria is 
that of identification of risk factors that accelerate the 
onset of chronic complications like DN and institution of 
measures to retard its progression to ESRD. Dyslipidemia 
using World Health Organization (WHO) criteria [serum 
triglyceride- 150-400 mg/dL (1.7-4.5 mmol/L), total 
cholesterol (TC) > 200 mg/dL (>5.2 mmol/L), low-density 
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disease after the initiating event has damaged the glomerular 
capillary wall, thereby allowing increased passage of lipids 
and lipoproteins into the renal mesangium.[5]
Details of the mechanism by which lipids cause or exacerbate 
glomerular injury are incompletely understood. In the 
human glomeruli, both mesangial and epithelial cells take 
up lipoproteins via specific receptors.[6] Mesangial cells 
express scavenger receptors, which are involved in the 
preferential uptake of modified glycosylated and oxidized LDL. 
Accumulation of modified LDL in the mesangium has been 
noted to favor their uptake by infiltrated glomerular monocytes, 
leading to activation of these cells into macrophages.[7] This 
preferential phagocytosis of modified LDL-C by monocytes 
has been reported to play a pivotal role in the formation 
of mesangial foam cells.[8] Second, accumulated modified 
lipoproteins within the mesangium stimulate mesangial cell 
secretion of various chemotactic factors and adhesion molecules 
(eg, macrophage colony stimulating factor, intracellular 
adhesion molecule-1), enhancing the renal recruitment of 
macrophages. These factors result in monocyte infiltration, 
which is reported to play a key role in the pathogenesis of 
glomerulosclerosis and tubular fibrosis, particularly in DN.[8] 
These intra-mesangial recruited macrophages may, in turn, 
further oxidize LDL creating a vicious self-perpetuating 
cycle resulting in progressive renal injury. Third, activated 
macrophages in the renal mesangium stimulate the release 
of reactive oxygen species and expression of prosclerotic and 
proliferative cytokines such as transforming growth factor B1 
(TGFB-1) and platelet-derived growth factor-AB (PDGF-
AB). These cytokines stimulate the production of extracellular 
matrix proteins, thereby promoting mesangial expansion as 
described in DN. in vitro studies have demonstrated that 
LDL and oxidized LDL stimulate TGF-B1 gene expression 
in human glomerular, mesangial, and epithelial cells. 
Therefore, TGF-B1 appears to be an important mediator of 
lipid-induced mesangial matrix expansion as well as play a 
key role in the pathogenesis of DN.[7,9] Finally, the uptake of 
modified LDL by mesangial macrophages has been reported 
to stimulate eicosanoid synthesis including thromboxanes and 
leukotrienes, leading to potentially deleterious alterations in 
intra-glomerular hemodynamics.[6]
The damaging effect of hyperlipidemia on the kidneys 
extends beyond the glomerulus. In the tubulointerstitium, 
animal studies have demonstrated that hyperlipidemia 
is associated with significant interstitial macrophage 
infiltration and increase in TGF-B1 gene expression in 
the interstitial cells suggesting a cytokine-mediated role of 
lipids in the development or aggravation of tubulointerstitial 
lesions.[10] Also, in overt DN, it has been proposed from 
experimental in vivo studies that the tubular uptake and 
metabolism of the lipid component of filtered lipoproteins 
lead to local expression of chemokines and cytokines 
and promote interstitial inflammation.[11] These findings 
in animal models, however, is cautiously extrapolated to 
humans because contrasting results have been observed 
in humans.[11]
Globally, statistics on the prevalence of dyslipidemia on a 
subpopulation of diabetic patients with overt nephropathy 
is scanty and, locally, it is even more so in Nigeria. Against 
this background, our study sought to determine the role 
of dyslipidemia as a risk factor for DN by determining 
the prevalence of dyslipidemia in Nigerian adult diabetic 
subjects with overt DN. It is hoped that the outcome of 
this study will draw attention to the need for aggressive 
management of dyslipidemia in DN patients.
Materials and Methods
A total of 342 diabetic patients that presented consecutively 
at the medical outpatient, diabetic, renal clinics, and admitted 
into the medical wards of the Nnamdi Azikiwe University 
Teaching Hospital Nnewi (NAUTH), were recruited for 
this study and screened for diabetic nephropathy. A total 
of 320 eligible and consenting patients were screened and 
72 satisfied the inclusion criteria for DN and were studied. 
Inclusion criteria were all known adult diabetic patients of 
both sexes, including newly presenting diabetic patients 
with overt proteinuria. Overt proteinuria was defined as 
albumin/creatinine ratio of >300 mg albumin per gram of 
creatinine on a spot urine sample.
Thirty-six diabetic patients with normoalbuminuria drawn 
from the total sample population by simple random sampling 
were studied as controls. They were age- and sex-matched 
with the subjects with overt DN. Normoalbuminuria was 
defined as urine albumin/creatinine ratio of <30 mg albumin 
per gram of creatinine on a spot urine sample.
Diabetes mellitus was diagnosed and grouped into Type 1 
or Type 2 using the WHO criteria.[12] Hypertension was 
defined as blood pressure ≥140/90 mmHg.[13] Urine samples 
were collected in clean urine containers for estimating the 
urine albumin/creatinine ratio. This was done as a spot 
urine collection, and about 20 ml of urine was collected 
and the samples were stored in the refrigerator at 4°C and 
later transported to the Chemical Pathology laboratory 
for analysis. Fasting blood samples were collected after a 
14-h overnight fast for estimation of fasting blood sugar, 
total cholesterol, triglycerides, HDL-cholesterol, and 
LDL-cholesterol. Blood samples for packed cell volume, 
electrolytes, urea, and creatinine were also collected. The kit 
used for the urine albumin/creatinine was from RANDOX 
Laboratories LTD, Diamond Road, Crumlin Co, Antrim 
UK, BT 294QY. Appropriate colorimetric kits for all four 
subsets of lipids were used and purchased from Biosystems 
S. A., Costa Brava, 30, Barcelona (Spain). Samples were 
assayed at the Chemical pathology laboratory of NAUTH 
Nnewi. Estimated glomerular filtration rate (eGFR) was 
calculated from the serum creatinine value assayed using the 
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Modification of diet in renal disease (MDRD)[14] abbreviated 
equation as follows:
186 × S (Cr)−1.154 × Age−0.203 × 0.742 (if female) × 1.210 
(if black).
The lipid assays were done using already standardized 
and well established methodology.[15] Measurement of 
total cholesterol was by cholesterol oxidase/peroxidase 
reaction, HDL-C was assayed using phosphotungstic acid 
in the presence of magnesium chloride to precipitate out 
very low-density lipoprotein (VLDL) and LDL-C. After 
centrifugation, the supernatant containing HDL was assayed 
for HDL-C. TG was assayed using enzymatic colorimetric 
method after hydrolysis of the triglycerides. LDL-C was 
calculated by indirect method using Friedewald et al.[16] 
equation, summarized as follows: LDL-C = (TC-HDL-C)-
(TG/2.2) all concentrations given in mmol/L.
Dyslipidemia was taken as serum triglyceride 150-
400 mg/dL (1.7-4.5 mmol/L), total cholesterol >200 mg/
dL (>5.2 mmol/L), LDL-cholesterol >135 mg/dL 
(>3.5 mmol/L), HDL-C < 35 mg/dL (<0.9 mmol/L) in 
men or <40 mg/dL (<1.0 mmol/L) in women.[4]
Data entry and analysis were done using SPSS statistical 
software version 13. Results are presented as frequency 
tables, mean ±SD, and means were compared using 
Students t test, while Chi-square was used to test for 
association and P ≤ 0.05 was considered significant.
Result
A total of 320 eligible and consenting diabetic patients were 
screened over a period of 12 months. Among those screened, 
27 (8.4%) were Type 1 DM patients, while 293 (91.6%) 
were Type 2. Of these, 72 had overt diabetic nephropathy. 
The prevalence of DN in this study was 22.5%. The mean 
age of the study group (DN present) was 55 ± 12 years 
compared to 52 ± 13 years in the control group. The peak 
age of occurrence of DN was in the age group of 40-49 years 
(27; 37% closely followed by the age group of 50-59 years 
(15; 20.8%). More females (51.4%) than males (48.6%) had 
DN and the sex distribution was also similar in the controls, 
with 55.6% females and 44.4% males. The difference in the 
age and gender distribution of the study and control subjects 
was not statistically significant (P = 0.35).
[Table 1] shows the lipid profile of subjects with and 
without DN. Mean TG of 1.98 mmol/L in subjects with DN 
was significantly higher than 1.63 mmol/L in the controls 
(P = 0.004). Mean TC was 5.05 mmol/L in DN patients 
compared to 4.57 mmol/L in the controls, and this difference 
was statistically significant (P = 0.04). Mean LDL-C and 
HDL-C in subjects and controls were similar. Mean LDL-C 
was 3.28 mmol/L in DN patients and 3.02 mmol/L in controls 
(P = 0.33), mean HDL-C was 0.95 mmol/L for the DN 
group and 0.86 mmol/L for the control group (P = 0.45).
[Table 2] compares the frequency distribution of dyslipidemia 
in the study and control subjects. Dyslipidemia was more 
prevalent in the diabetics with overt nephropathy. Elevated 
TC and hypertriglyceridemia were significantly more 
prevalent in DN subjects compared to subjects without DN 
(P = 0.003 and P = 0.002, respectively). Although LDL-C 
was more elevated in those with DN (45.8%), compared 
with controls (38.9%), this difference was not statistically 
significant (P = 0.49). Lower levels of serum HDL-C 
was more prevalent in the controls (69.4%) than the DN 
group (58.3%), but this difference was not significant too 
(P = 0.26).
The mean eGFR of those with DN was 39.72 ± 10.30 
ml/min/1.73 m², while that of the control subjects was 
67.18 ± 20.25 ml/min/1.73 m²; this difference was 
statistically significant (P = 0.0001). A majority (80.9%) 
of patients with DN were either in stages 3 or 4 of chronic 
kidney disease, while 86.1% of the control patients were 
in stage 2 or 3 chronic kidney disease. None of the control 
subjects were in stages 4 or 5 chronic kidney disease.
The mean albumin creatinine ratio for those with diabetic 
nephropathy was 388.99 ± 54.87 and 19.95 ± 5.97 for 
those without diabetic nephropathy (P = 0.0001).
Table 1: Lipid profile of subjects with and without DN
Serum lipid (mmol/l) Diabetic nephropathy t and  
P valuesPresent Absent
Triglyceride Mean 1.98 1.63 t = 2.73
(TG) SD 0.78 0.46 P = 0.004
Total cholesterol Mean 5.05 4.57 t = 1.99
(TC) SD 1.17 1.18 P = 0.049
LDL Mean 3.28 3.02 t = 0.99
SD 1.71 1.29 P = 0.33
HDL Mean 0.95 0.86 t = 0.75
SD 0.55 0.68 P = 0.45
Table 2: Frequency distribution of dyslipidemia in 
diabetics with and without DN










Triglyceride Dyslipidemia 48 (66.7) 13 (36.1) 61 (56.5) X2 = 9.12
Normal 24 (33.3) 23 (63.9) 47 (43.5) P = 0.003
Total 
cholesterol
Dyslipidemia 45 (62.5) 11 (30.6) 56 (51.9) X2 = 9.81 
Normal 27 (37.5) 25 (69.4) 52 (48.1) P = 0.002
LDL Dyslipidemia 33 (45.8) 14 (38.9) 47 (43.5) X2 = 0.47 
Normal 39 (54.2) 22 (61.1) 61 (56.5) P = 0.49
HDL Dyslipidemia 42 (58.3) 25 (69.4) 67 (62.0) X2 = 1.26
Normal 30 (41.7) 11 (30.6) 41 (38.0) P = 0.26
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Discussion
Previous studies have shown conclusively that lipid 
abnormalities in patients with diabetes mellitus is a major 
problem and associated with increased risk of cardiovascular 
disease.[15] The most common pattern of dyslipidemia in 
such patients consists of elevated levels of serum triglyceride 
(TG) and low levels of HDL-C. The result of our study, 
apart from agreeing with earlier reports that dyslipidemia is 
prevalent in diabetic patients, also shows that dyslipidemia 
is more severe among diabetic patients with DN than 
diabetic patients without DN. Using the WHO[4] cut-
off values for hypercholesterolemia, 66.7% of the study 
population with overt DN had hypertriglyceridemia, 62.5% 
had hypercholesterolemia, 45.8% had elevated LDL-C, 
and 58.3% had decreased HDL-C. These values were by 
far higher than those observed in the control group, with 
the exception of HDL-C. Among the control group, 36.1% 
had hypertriglyceridemia, 30.6% had hypercholesterolemia, 
38.9% had elevated LDL-C, and 69.4% had decreased 
HDL-C.
The pattern of dyslipidemia observed in our study 
was similar to reports from Saudi Arabia,[17,18] where 
the incidence of dyslipidemia was noted to be in the 
range of 25-60% among diabetic patients. There 
was also some similarity with results of Lipid Research 
Clinic Prevalent studies, where lipids and lipoprotein 
abnormality rates were approximately 25% and 50% for TG 
and total cholesterol, respectively.[19] Studies from Nigeria 
have reported similar findings, where hypercholesterolemia 
was present in 43.5% and hypertriglyceridemia in 34.8% of 
patients with Type 2 DM.[2]
The combination of hypercholesterolemia and hyper-
triglyceridemia found in DN patients in this study is similar 
to that reported in the Saudi Arabian study,[17,18] where 
significantly higher levels of TG and TC were noted 
among patients with DN. This also agrees with reports 
from the Diabetes Control and Complications Trial/
Diabetes Interventions and Complications Study (DCCT/
EDIC)[20,21] cohort group study, where the lipid profile 
relating to albumin excretion rate (AER) is elevated TG, 
TC, and LDL-C. The severe dyslipidemia noted in patients 
with DN is similar to that shown by earlier researchers 
who reported significantly higher plasma concentrations 
of TG, VLDL, LDL, and lower levels of HDL-C in 
incipient and overt macroalbuminuric compared to 
normoalbuminuric diabetic patients. [22,23] It has been 
suggested that these findings may be related to reduced 
metabolic processes and impaired excretion of metabolic 
waste products worsened by poor glycemic control, insulin 
resistance, and poor control of hypertension observed 
in their study population.[22,23] The progression of DN 
seems to be linked with serum lipids and is thought to be 
independent of glycemic and blood pressure control. [24] 
The nature of the lipid interaction was also noted 
to be different at various stages of renal disease. DN 
progression in normoalbuminuric patients was linked to 
the LDL-C; in microalbuminuric subjects, it was linked 
to the TG content of VLDL and IDL particles; and in 
macroalbuminuric patients, progression to ESRD was 
associated with LDL size but not with triglyceride-linked 
indexes. This observation is consistent with the findings 
of Coonrod et al.[25]who reported that TG and cholesterol 
had different effects on the progression of nephropathy, 
depending on the duration of diabetes. The results of 
this study, however, did not and could not assess causal 
relationship because it was not a prospective study.
Conclusions
This study showed clearly that lipoprotein abnormalities 
are highly prevalent in adult Nigerian diabetic patients with 
normoalbuminuria and macroalbuminuria and more so in 
diabetics with macroalbuminuria. Aggressive management 
of dyslipidemia in diabetic subjects, especially those 
with overt nephropathy, may retard their progression to 
ESRD. For those with normoalbuminuria, it may prevent 
progression to overt DN.
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